GlassScriptPhysician profile
Veronica Moino
NPI 1518584465
$1,530.23
in general payments reported to CMS, 2019-2025
25 companies · $347 in 2025
The $347 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $237 · 2024: $946 · 2025: $347.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,530.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,530.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $347.29 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $220.26 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $175.65 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $142.57 | 2023-2025 | Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $110.46 | 2024 | Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.77 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $51.99 | 2024 | |
| Exact Sciences Corporation | $44.54 | 2025 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $32.26 | 2023-2024 | Quviviq |
| Axsome Therapeutics, INC. | $31.89 | 2024 | Sunosi |
| Pfizer INC. | $27.65 | 2023-2024 | |
| Astellas Pharma US INC | $27.57 | 2025 | Veozah |
| Otsuka America Pharmaceutical, INC. | $27.12 | 2023 | Rexulti |
| Acadia Pharmaceuticals INC | $22.20 | 2025 | Nuplazid |
| Amgen INC. | $20.77 | 2024 | Repatha, Otezla |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verity Pharmaceuticals INC. | $19.79 | 2025 | Tlando |
| Inari Medical, INC. | $18.98 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Daiichi Sankyo INC. | $18.72 | 2024 | Injectafer |
| Dexcom, INC. | $18.19 | 2023 | Dexcom G6 Transmitter |
| Tris Pharma INC | $17.93 | 2024 | Dyanavel Xr |
| Esperion Therapeutics, INC. | $17.15 | 2024 | Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.58 | 2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $14.19 | 2025 | Voquezna |
| Tolmar, INC. | $13.98 | 2024 | |
| Halozyme INC | $13.73 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Veronica Moino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.